Skip to main content
. 2019 Mar 26;25(8):876–883. doi: 10.1111/cns.13120

Figure 2.

Figure 2

Prognostic value of neutrophil‐to‐lymphocyte ratio (NLR) in Sanbo (group1, N = 260) and Tiantan (group2, N = 66) cohorts. A, Patients (grade II‐IV from Sanbo Brain Hospital), B, High grade (grade III‐IV) patients (from Sanbo Brain Hospital) and C, Patients (grade II‐IV from Tiantan Hospital) with higher NLR showed worse prognosis (A, NLR <3.2 group, N = 162, median survival: 784 days; NLR >3.2 group, N = 46, median survival: 436 days; P = 0.0093; B, NLR <3.2 group, N = 115, median survival: 784 days; NLR >3.2 group, N = 40, median survival: 436 days, P = 0.0367; C, NLR <3.2 group, N = 26, median survival: 713.5 days; NLR >3.2 group, N = 40, median survival: 416.5 days, P = 0.0205)